Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A RANDOMİZED CONTROLLED TRİAL COMPARİNG THE EFFECTİVENESS OF MYOFASCİAL RELEASE, LOW-LEVEL LASER THERAPY, AND PELOİD THERAPY İN PATİENTS DİAGNOSED WİTH MİLD TO MODERATE CARPAL TUNNEL SYNDROME

12 novembre 2026 aggiornato da: RAİKAN BÜYÜKAVCI, Konya Beyhekim Training and Research Hospital

This randomized controlled trial aims to compare the effectiveness of low-level laser therapy (LLLT), myofascial release (MFR), and peloid therapy in patients diagnosed with mild to moderate carpal tunnel syndrome (CTS). A total of 84 eligible participants aged 18-65 years will be randomly assigned to one of three treatment groups. Group 1 (LLLT): Patients will receive low-level laser therapy 5 days a week for 3 weeks (total 15 sessions). Group 2 (Myofascial Release): Patients will receive manual myofascial release therapy 3 days a week for 5 weeks. Group 3 (Peloid Therapy): Patients will receive peloid (mud) therapy at 45°C for 20 minutes, 5 days a week for 3 weeks (total 15 sessions). Clinical evaluations will be performed at baseline, at the end of the treatment (15th session), and at the 12-week follow-up. The primary outcome measures are the Boston Carpal Tunnel Questionnaire (BCTSQ) and Jamar dynamometer grip strength. Secondary outcome measures include ultrasonographic median nerve cross-sectional area (CSA) and electrophysiological nerve conduction studies (EMG).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Background and Rationale: Carpal Tunnel Syndrome (CTS) is the most common peripheral nerve entrapment syndrome, resulting from the compression of the median nerve at the wrist. Conservative treatment options play a primary role in the management of mild to moderate CTS, aiming to reduce pain, alleviate symptoms, and improve functional status without immediate surgical intervention. This single-center, randomized controlled trial aims to compare the clinical and objective effectiveness of three distinct conservative modalities-low-level laser therapy (LLLT), myofascial release (MFR), and peloid therapy-routinely used in clinical practice. Study Design and Participants: A total of 84 male and female patients aged 18-65 years diagnosed with mild to moderate CTS at the Department of Physical Medicine and Rehabilitation, SBÜ Konya Beyhekim Training and Research Hospital, will be enrolled. Participants will be randomized into three intervention groups using a computer-generated randomization scheme. Intervention Groups:• Group 1 (Low-Level Laser Therapy - LLLT): Patients will receive LLLT administered by an experienced technician 5 days a week for 3 weeks (15 sessions in total). Treatment will be applied using a gallium-aluminum-arsenide (GaAlAs) diode laser emitting infrared light at an 860 nm wavelength, 1 kHz frequency, and 100 mW power output. The dosage will be 3.6 J/cm2, applied perpendicular to the skin over an area of approximately 15-20 cm2 for 40 seconds, with a total session duration of 120 seconds. • Group 2 (Myofascial Release - MFR): Patients will receive manual myofascial release therapy performed by an experienced physician 3 days a week for 5 weeks (15-30 minutes per session). The intervention will involve identifying tight muscle bands and trigger points in the wrist and forearm, applying direct pressure, gentle stretching, and implementing specific nerve and tendon gliding exercises. • Group 3 (Peloid Therapy): Patients will receive medical peloid therapy (sourced from Köyceğiz, Muğla, rich in organic/inorganic substances and humic acid) applied 5 days a week for 3 weeks (15 sessions in total). A 1.5-2 cm thick layer of peloid heated to 45°C will be applied to the affected extremity, wrapped with a plastic bag and towel for 20 minutes, followed by gentle cleansing with warm water. Outcome Measures and Evaluation Schedule: Evaluations will be performed at baseline, at the end of the treatment (15th session), and at the 12-week follow-up. • Primary Outcome Measures: Symptom severity and functional status assessed via the Boston Carpal Tunnel Questionnaire (BCTSQ), and maximum grip strength measured objectively using a Jamar dynamometer. • Secondary Outcome Measures: Ultrasonographic assessment of the median nerve cross-sectional area (CSA) at the wrist level and electrophysiological nerve conduction studies (EMG) performed at the 12-week control.

Tipo di studio

Interventistico

Iscrizione (Stimato)

88

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: RAİKAN BÜYÜKAVCI, MD, Prof.
  • Numero di telefono: 4042 +90-0332-224-30-00
  • Email: rsoydemir@yahoo.com

Luoghi di studio

      • Konya, Turchia (Türkiye), 42000
        • Reclutamento
        • University of Health Sciences, Konya Beyhekim Training and Research Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age between 18 and 65 years.
  • Diagnosis of mild or moderate Carpal Tunnel Syndrome (CTS) confirmed by electrophysiological tests (EMG).
  • Symptoms persisting for at least 3 months.
  • No prior history of surgical treatment for carpal tunnel syndrome.

Exclusion Criteria:

  • Severe carpal tunnel syndrome detected by electrophysiological tests.
  • History of severe trauma, fracture, or surgery in the same extremity within the last 6 months.
  • Having received physical therapy (TENS, laser, exercise, etc.) or injection therapy for CTS within the last 3 months.
  • Pregnant or lactating women.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Low-Level Laser Therapy (LLLT) Group

Patients in this group will receive low-level laser therapy (LLLT) administered 5 days a week for 3 weeks, totaling 15 sessions. The treatment will be applied using a gallium-aluminum-arsenide (GaAlAs) diode laser emitting infrared light.

Low-level laser therapy administered 5 days a week for 3 weeks (total 15 sessions) using a GaAlAs diode laser.

Comparatore attivo: Myofascial Release (MFR) Group

Patients in this group will receive manual myofascial release (MFR) therapy performed 3 days a week for 5 weeks. The intervention involves identifying tight muscle bands and trigger points in the wrist and forearm, applying direct manual pressure, gentle stretching, and specific nerve and tendon gliding exercises.

Manual myofascial release therapy performed 3 days a week for 5 weeks, including trigger point release and neural/tendon gliding exercises.

Comparatore attivo: Peloid Therapy Group

Patients in this group will receive medical peloid (mud) therapy applied 5 days a week for 3 weeks, totaling 15 sessions. A 1.5-2 cm thick layer of peloid heated to 45°C will be applied to the affected extremity, wrapped for 20 minutes, and then gently cleansed with warm water.

Medical peloid therapy applied at 45°C for 20 minutes, 5 days a week for 3 weeks (total 15 sessions).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Boston Carpal Tunnel Questionnaire (BCTSQ) Score
Lasso di tempo: Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.

Assessment of symptom severity and functional status using the Boston Carpal Tunnel Questionnaire (BCTSQ), which consists of a Symptom Severity Scale (11 items) and a Functional Status Scale (8 items), scored from 1 (best) to 5 (worst).

Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.
Maximum Grip Strength
Lasso di tempo: Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.

Objective measurement of maximum hand grip strength evaluated using a Jamar dynamometer (recorded in kilograms or pounds).

Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Ultrasonographic Median Nerve Cross-Sectional Area (CSA)
Lasso di tempo: Baseline and at the 12-week follow-up.

Assessment of the median nerve cross-sectional area (CSA) at the wrist level using high-resolution ultrasonography to evaluate structural changes and reduction in nerve swelling.

Baseline and at the 12-week follow-up.
Electrophysiological Nerve Conduction Parameters (SNCV, SNAP, CMAP, DML)
Lasso di tempo: Baseline and at the 12-week follow-up.

Evaluation of median nerve conduction characteristics, including sensory nerve conduction velocity (SNCV), sensory nerve action potential (SNAP) amplitude, compound muscle action potential (CMAP) amplitude, and distal motor latency (DML).

Baseline and at the 12-week follow-up.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: ERDİ İNCİGÜZ, M.D., University of Health Sciences, Konya Beyhekim Training and Research Hospital
  • Cattedra di studio: RAİKAN BÜYÜKAVCI, MD, Prof., University of Health Sciences, Konya Beyhekim Training and Research Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

5 marzo 2026

Completamento primario (Stimato)

1 marzo 2027

Completamento dello studio (Stimato)

1 luglio 2027

Date di iscrizione allo studio

Primo inviato

12 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • KonyaBeyhekimTRH/01-21

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Prerequisites / What data will be shared:De-identified individual participant data (including demographic data, baseline and follow-up Boston Carpal Tunnel Questionnaire scores, Jamar grip strength measurements, ultrasonographic median nerve cross-sectional area [CSA] values, and electrophysiological nerve conduction parameters) underlying the results reported in the future publication will be shared.Supporting Documents:Study Protocol and Informed Consent Form will also be available upon request.Time Frame:Available beginning 3 months and ending 5 years following article publication.Access Criteria:Requests should be directed to the corresponding author via email. Data will be shared with researchers whose proposed use of the data has been approved by the principal investigator and institutional ethics committee, provided that a signed data access agreement is established.

Periodo di condivisione IPD

Available beginning 3 months and ending 5 years following article publication.

Criteri di accesso alla condivisione IPD

Requests should be directed to the corresponding author via email. De-identified individual participant data will be shared with researchers whose proposed use of the data has been approved by the principal investigator and institutional ethics committee, upon the establishment of a signed data access agreement.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .